| Literature DB >> 35025857 |
Shahla M Jilani, Kristina West, Laura Jacobus-Kantor, Mir M Ali, Alice Nyakeriga, Heather Lake-Burger, Meagan Robinson, A Elise Barnes, Tracey Jewell, Shayne Gallaway.
Abstract
Opioid use disorder (OUD) is a significant public health problem in the United States, which affects children as well as adults. During 2010-2017, maternal opioid-related diagnoses increased approximately 130%, from 3.5 to 8.2 per 1,000 hospital deliveries, and neonatal abstinence syndrome (NAS) increased 83%, from 4.0 to 7.3 per 1,000 hospital deliveries (1). NAS, a withdrawal syndrome, can occur among infants following in utero exposure to opioids and other psychotropic substances (2). In 2018, a study of six states with mandated NAS case reporting for public health surveillance (2013-2017) found that mandated reporting helped quantify NAS incidence and guide programs and services (3). To review surveillance features and programmatic development in the same six states, a questionnaire and interview with state health department officials on postimplementation efforts were developed and implemented in 2021. All states reported ongoing challenges with initial case reporting, limited capacity to track social and developmental outcomes, and no requirement for long-term follow-up in state-mandated case reporting; only one state instituted health-related outcomes monitoring. The primary surveillance barrier beyond initial case reporting was lack of infrastructure. To serve identified needs of opioid- or other substance-exposed mother-infant dyads, state health departments reported programmatic successes expanding education and access to maternal medication for opioid use disorder (MOUD), community and provider education or support services, and partnerships with perinatal quality collaboratives. Development of additional infrastructure is needed for states aiming to advance NAS surveillance beyond initial case reporting.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35025857 PMCID: PMC8757621 DOI: 10.15585/mmwr.mm7102a1
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586
Features of neonatal abstinence syndrome case reporting — six states,* 2018–2021†
| State (yr)§ | Reporting timeliness,¶ | Reporting criteria: clinician diagnosis** | Case follow-up†† | Estimated completeness of case capture,§§ % | Use of case reports | |
|---|---|---|---|---|---|---|
| To determine NAS incidence, community substance use patterns, and guide program development | To characterize mother-infant hospital discharge disposition | |||||
| Arizona (2017) | Unknown | Yes | None | 50–75 | Yes | No |
| Florida (2014) | 180 | Yes | None | >75 | Yes | No |
| Georgia (2017) | 51 | Yes: infant toxicology positive.*** transitioning to CSTE case reporting definition.††† | None | >75 | Yes | No |
| Kentucky (2014) | 66 | Yes | None | >75 | Yes | Yes |
| Tennessee (2017) | 28 | Yes: transitioning to CSTE case reporting definition.††† | None | >75 | Yes | No |
| Virginia (2017) | 30 | Yes | None | >75 | Yes | No |
Abbreviations: CSTE = Council of State and Territorial Epidemiologists; NAS = neonatal abstinence syndrome.
* Arizona, Florida, Georgia, Kentucky, Tennessee, and Virginia.
† The six states that implemented mandatory NAS reporting during 2013–2017 were invited for voluntary participation in a follow-up questionnaire and telephone interview to review NAS case reporting and surveillance from May 2018 to February 2021.
§ Year legal NAS case reporting mandate became effective; Florida had passive NAS case reporting system from the Agency for Health Care Administration within 6 months of diagnosis.
¶ Average number of days from the time of NAS diagnosis to case report.
** Medical provider diagnosis regardless of whether infant required or was given specific treatment.
System or standard operating procedure in place for follow-up of infants with diagnosed NAS or their families once state health department has been notified of the case.
§§ Capture of total case incidence rate via case reporting compared with hospital discharge records.
Timeliness is unknown because state-level resources to analyze and monitor completeness received limited NAS case reports.
*** For Georgia, infants with positive toxicology or clinician diagnosis of NAS are reported.
††† https://cdn.ymaws.com/www.cste.org/resource/resmgr/2019ps/final/19-MCH-01_NAS_final_7.31.19.pdf
Features of state-led surveillance of neonatal abstinence syndrome in states with mandated reporting* — six states, 2018–2021
| Program feature | Surveillance findings reported by health officials† | States implementing surveillance feature |
|---|---|---|
| Ongoing challenges with initial case reporting§ | ||
| Resource-intensive activities (surveillance-related activities requiring the most state resources) | Collecting missing information (infant) | Arizona, Georgia, Tennessee, Virginia |
| Collecting missing information (mother) | Arizona, Georgia, Tennessee, Virginia | |
| Assessing data accuracy (medical record abstraction) | Florida | |
| Sharing reports with local, state, and federal agencies | Tennessee | |
| Deduplicating data received from multiple facilities and medical providers | Georgia, Kentucky, Virginia | |
| Tracking and reconnecting with families of infants relocating within state | Arizona, Virginia | |
| Barriers to initial case reporting | Lack of capacity to carry out medical record abstractions | Tennessee |
| Limited awareness of surveillance efforts by facilities, medical providers, or staff turnover | Georgia, Kentucky | |
| Variability in case identification and reporting by facility | Georgia | |
| Passive surveillance registry limits timeliness, accuracy, and data completeness | Florida | |
| Challenges with criteria or implementation of NAS case definition | Arizona, Georgia | |
|
| ||
| Health-related outcomes¶ (e.g., maternal OUD or SUD, initiation or retention in MOUD program, infant hospitalization rates and comorbidities) | Monitoring comorbidities in infants with NAS | Kentucky |
| Monitoring infant hospitalization rates | Kentucky | |
| Monitoring rates of infant preventative health maintenance visit, vaccine information | Kentucky | |
| Social services-related outcomes¶ (e.g., linkage to housing, transportation, food or nutrition, child welfare, legal assistance, or juvenile courts services) | N/A | None |
| Development-related outcomes¶ (e.g., linkage or retention in Head Start, early intervention, home nursing visitation services) | N/A | None |
| Program development or improvement activities informed by state NAS surveillance** (to serve identified needs of opioid or substance-exposed mother-infant dyads) | OUD education campaign (e.g., stigma reduction) for providers and families | Arizona, Kentucky, Tennessee |
| Expand MOUD programs for pregnant or postpartum women | Arizona, Florida | |
| Educational outreach to local MOUD providers and jails for expanded access to contraception for persons voluntarily seeking contraception | Tennessee | |
| Educational or training outreach to hospitals participating in quality improvement program initiative to improve care management for NAS | Georgia | |
| Teleconsultation program for providers on maternal substance use prevention and treatment | Virginia | |
| Plan of Safe Care program designed specifically to identify OUD in pregnancy and link to MOUD | Florida | |
| Expand reimbursement for OUD screening or intervention | Florida | |
| Policy enactment informed by state NAS surveillance** (to address needs of opioid or substance-exposed mother-infant dyads) | Broadened same-day long-term contraception availability through state Medicaid program | Tennessee |
| Barriers to follow-up of initial case reports | Lack of infrastructure within agency to conduct follow-up with families of infants with reported cases of NAS | Arizona, Florida, Georgia, Tennessee, Virginia |
| Lack of infrastructure at outside agencies that provide services to families of infants | Arizona, Virginia | |
| Lack of access to necessary infrastructure or services in rural communities | Kentucky, Tennessee | |
|
| ||
| Institution of required data fields | + Collecting missing data | Kentucky, Tennessee |
| Link case report data to vital records | + Collecting missing data | Kentucky, Tennessee |
| Health official review of reported cases | - Requiring more resources to carry out activity | Kentucky, Tennessee |
| Request additional or missing information | - Collecting missing data; burdensome, inefficient | Georgia, Tennessee |
| Reporter education on best practices to complete case report | + Collecting missing data and data quality | Georgia, Tennessee |
| Partnering with national laboratories to receive positive toxicology for infant via ELR | + Enabling confirmation of select reported results and identification of cases that may have been otherwise missed | Georgia |
| - Laborious to set up | ||
| Tools or resources used (local or community or state-level resources used in conducting surveillance) | + Partnering with reporting hospital staff | Georgia, Tennessee |
| + Using web-based electronic reporting tools | Georgia, Kentucky, Tennessee | |
| - Faxing reports | Kentucky | |
| + Partnering with state perinatal quality collaborative | Florida, Georgia, Kentucky, Tennessee, Virginia | |
| + Using existing state disease reporting system streamlines hospital reporting | Arizona | |
| + State mandate for NAS public health reporting | Arizona, Georgia, Tennessee, Virginia | |
Abbreviations: ELR = electronic laboratory reporting; MOUD = medication for opioid use disorder; NAS = neonatal abstinence syndrome; OUD = opioid use disorder; SUD = substance use disorder; + = most helpful; − = least helpful.
* Arizona, Florida, Georgia, Kentucky, Tennessee, and Virginia.
† Surveillance findings listed are summarized from responses to questionnaires and semistructured interviews completed by state health departments.
§ Including and extending beyond initial case reporting; surveillance features listed are summarized from question items detailed in both questionnaire and semistructured interview completed by state health departments.
¶ Monitoring of specified outcomes since enactment of state-mandated NAS case reporting.
** Programs developed or policies enacted since institution of state-mandated NAS case reporting.
†† Quality assurance measures enacted to improve completeness of case reporting.